CABAZITAXEL DR.REDDY'S cabazitaxel 60 mg/1.5 mL concentrated injection vial

País: Australia

Idioma: inglés

Fuente: Department of Health (Therapeutic Goods Administration)

Ingredientes activos:

cabazitaxel, Quantity: 60 mg

Disponible desde:

Dr Reddys Laboratories Australia Pty Ltd

formulario farmacéutico:

Injection, concentrated

Composición:

Excipient Ingredients: polysorbate 80; citric acid

Vía de administración:

Intravenous Infusion

Unidades en paquete:

1

tipo de receta:

(S4) Prescription Only Medicine

indicaciones terapéuticas:

Cabazitaxel Dr.Reddy?s in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer previously treated with a docetaxel containing regimen.

Resumen del producto:

Visual Identification: Clear yellow to brownish-yellow viscous solution.; Container Type: Multiple containers; Container Material: Glass; Container Life Time: 36 Months; Container Temperature: Store below 30 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Estado de Autorización:

Registered

Fecha de autorización:

2018-07-23